Journal of Liposome Research · 2010 · 12 citations · 42 references
PharmacyImmunologyPharmacologyDrug DeliveryImmunizationInflammationLiposomal FormulationsLiposome-based DeliveryVaccinationVaccine DeliveryVaccine Delivery SystemsVaccine FormulationAdjuvant DeliveryAluminum Salt AdjuvantsAluminum SaltsCationic LiposomesCell Viability AssaysLiposome AdjuvantsLiposome ToxicityLiposomes
Vaccine development today encounters a main obstacle, which is the need for effective adjuvants suitable for clinical trials. Aluminum salts, discovered 70 years ago and, very recently, MF59, are the only types of adjuvants currently used in vaccines licensed by the U.S. Food and Drug Administration. Liposomes represent an alternative approach to vaccine adjuvants. In this article, we describe the inflammatory response and biological effect of polymerization and the addition of positive charges in liposome formulations. Nonpolymerized cationic (NP(+)) liposomes significantly reduce metabolism in Vero cells after 24 hours. Correspondingly, both NP(+) and polymerized cationic (P(+)) liposomes reduce cell viability following a 48-hour incubation. Similar results were obtained with cells from the peritoneal cavities of mice. Paradoxically, those liposomes that presented clearly cytostatic or cytotoxic effects in vitro stimulated metabolism and had a mitogenic effect in vivo. Finally, the adjuvant effect was tested by immunization in BALB/c mice. The major effect was obtained with NP(+) liposomes. Accordingly, we also demonstrated that NP(+) liposomes injected into the dermis produced an outstanding inflammatory reaction, showing the histopathological characteristics of an inoculation granuloma. Thus, positive charge would play an important role in the immunoadjuvant effect of liposomes by conferring them cytotoxic capacity.
42
HMGB1 is an endogenous immune adjuvant released by necrotic cells
Patrizia Rovere‐Querini, Annalisa Capobianco, Paola Scaffidi et al. · EMBO Reports · 2004 · 584 citations · Full text
Primary structures of three human neutrophil defensins.
Michael E. Selsted, S S Harwig, Tomas Ganz et al. · Journal of Clinical Investigation · 1985 · 531 citations · Full text